Generic Name and Formulations:
Leuprolide acetate 22.5mg; depot susp for IM inj.
Palliative treatment of advanced prostatic carcinoma.
22.5mg IM inj every 3 months (84 days). Do not split doses.
Metastatic vertebral lesions. Urinary obstruction. Monitor serum testosterone, PSA, acid phosphatase. Increased risk of diabetes, MI, sudden cardiac death, stroke; monitor blood glucose, HbA1c, and for signs/symptoms of CVD during therapy. History of seizures. Risk of QT prolongation: long-term androgen deprivation therapy, congenital long QT syndrome, electrolyte abnormalities, or CHF. Correct and monitor electrolyte abnormalities; consider monitoring ECGs. Instruct patient on correct self administration. Nursing mothers: not recommended.
Concomitant antiarrhythmics may prolong the QT interval.
Hot flashes/sweats, inj site reaction, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), edema, GI disorders, pain, cardiovascular events, CNS and antiandrogenic effects, asthenia, testicular atrophy, urinary disorders, spinal cord compression; hyperglycemia, anaphylactoid, photosensitivity.
Depot kit—1 (prefilled dual-chamber syringe w. supplies)
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
Fever in adults can have potentially serious causes, ranging from sepsis to malignancy. Dr Pipin Singh...
In this article Dr Pipin Singh advises on how to identify red flags in patients presenting with bone...
Dr Matthew West covers the red flags to look out for in pregnancy, including back pain, bleeding, headaches...
This article, updated in 2016 by Dr Anthony De Soyza, advises on causes, investigations and managing...
Dr Keith Barnard discusses the aetiology and symptoms of Brugada syndrome. Key learning points for GPs...
Dr Kirsty Le Doare and Dr Nuria Martinez-Alier describe the signs and symptoms of measles and outline...